Biontech Se Sponsored Adr Stock News

BioNTech SE and Regeneron Pharmaceuticals Inc. said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron''s Libtayo in patients with advanced non-small cell lung cancer, starting with a Phase 1/2 clinical trial. Libtayo is approved in the U.S. to treat advanced basal cell carcinoma. The companies already have an agreement evaluating this combination in patients with advanced melanoma. Both companies have generated billions of dollars in revenue from COVID-19 vaccines and treatments over the course of the pandemic. So far this year, BioNTech''s stock has tumbled 51.0%, while shares of Regeneron are down 2.0%. The S&P 500 has declined 8.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

On Tuesday, German vaccine maker BioNTech (BNTX) announced an expansion of its strategic collaboration with Regeneron (REGN) to add advanced non-small cell lung cancer ((NSCLC))…

MAINZ, Germany , March 8, 202 2 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration with Regeneron to advance the Company’s FixVac candidate BNT116 in combination with Libtayo ® (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement the companies plan to jointly conduct clinical trials to evaluate their combination in different patient populations with advanced NSCLC. Lung cancer is worldwide one of the most common diagnosed malignant cancer types and the leading cause of cancer death. 1 NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers.

BioNTech SE BNTX, -1.36% and Regeneron Pharmaceuticals Inc. REGN, -0.58% said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron's Libtayo in patients with advance

Investors are concerned that the company's revenue will plunge as the need for its COVID-19 vaccine diminishes.

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Investors were spooked by the government''s plan to share certain COVID treatment technologies with international health organizations.

Investors were spooked by the government's plan to share certain COVID treatment technologies with international health organizations.

Is this company just a coronavirus play?

Is this company just a coronavirus play?

The vaccine''s efficacy against infection among those children declined to 12 per cent at the end of January from 68 per cent in mid-December compared to kids who did not get vaccinated The post Pfizer/BioNTech COVID vaccine less effective in kids aged five to 11 years: New York study appeared first on Express Pharma .

According to a published study, Pfizer Inc (NYSE: PFE ) and BioNTech SE''s (NASDAQ: BNTX ) two-dose COVID-19 vaccine provided very little protection for children aged 5 to 11 years during the wave of omicron infection in New York. The vaccine''s efficacy against infection among those children declined to 12% at the end of January from 68% in mid-December compared to kids who did not get … Full story available on Benzinga.com

TWO DOSES of the Pfizer, Inc. and BioNTech SE coronavirus disease 2019 (COVID-19) vaccine was protective against severe disease in children aged 5 to 11 during the recent Omicron variant surge, but quickly lost most of its ability to prevent infection in the age group, according to a study by New York State researchers.

Two doses of the Pfizer Inc and BioNTech COVID-19 vaccine was protective against severe disease in children aged 5 to 11 during the recent omicron variant surge, but quickly lost… Read more » The post Study: Pfizer/BioNTech COVID Vaccine Less Effective in Ages 5-11 appeared first on Hamodia .

The COVID-19 vaccine developed by Pfizer and German partner BioNTech SE is much less effective in preventing infection in children aged 5 to 11 than in older people, according to a new dataset from health officials in New York state, the New York Times reported. For now, the Pfizer/BioNTech shot is the only one authorized for use in that age group. And while it still protects against severe disease, it offers hardly any protection against infection, even within a month after full immunization, according to the data, which were collected during the recent surge caused by the highly infectious omicron variant. The vaccine''s poorer performance may stem from the fact that children are given one-third the dose offered to older children and adults, officials and researchers said, [l: according to the Times. The vaccine has also performed weakly in children aged 2 to 4 years old, who were given an even smaller dose. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.